Principal Financial Group
AEGR

Principal Financial Group’s Aegerion Pharmaceuticals AEGR Stock Holding History

Principal Financial Group’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-6,100
Closed -$204K – 2259
2014
Q3 		$204K Buy
+6,100
New +$189K ﹤0.01% 2024
2014
Q2 		– Sell
-8,982
Closed -$414K – 2360
2014
Q1 		$414K Sell
8,982
-86
-0.9% -$5.04K ﹤0.01% 1907
2013
Q4 		$643K Hold
9,068
– – ﹤0.01% 1837
2013
Q3 		$777K Sell
9,068
-859
-9% -$72.8K ﹤0.01% 1777
2013
Q2 		$629K Buy
+9,927
New +$527K ﹤0.01% 1792

Other funds holding AEGR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Principal Financial Group's AEGR Position: Q4 2014 in Review

Principal Financial Group sold out of Aegerion Pharmaceuticals (AEGR) in Q4 2014, closing a stake of 6,100 shares — an estimated $204K sold.

Principal Financial Group first reported a position in AEGR in Q2 2013 and held it in 5 quarters. The position peaked at $777K in Q3 2013. 95 funds tracked by Wall St. Rank hold AEGR as of Q4 2014.

  • Principal Financial Group reported no remaining Aegerion Pharmaceuticals position as of Q4 2014 after selling out during the quarter.
  • Principal Financial Group sold 6,100 Aegerion Pharmaceuticals shares in Q4 2014, an estimated $204K.
  • Principal Financial Group first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 5 quarters.
  • Principal Financial Group's Aegerion Pharmaceuticals position peaked at $777K in Q3 2013.
  • 95 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2014.

Based on Principal Financial Group's 13F filing for Q4 2014, filed 12 Feb 2015.